|
KMID : 0366220130480030185
|
|
Korean Journal of Hematology
2013 Volume.48 No. 3 p.185 ~ p.192
|
|
|
Evaluation of prognostic factors in patients with therapy-related acute myeloid leukemia
|
|
Park Sang-Hyuk
Chi Hyun-Sook
Cho Young-Uk
Jang Seong-Soo
Park Chan-Jeoung
|
|
|
Abstract
|
|
|
The clinical manifestation of therapy-related AML (t-AML) can generally be divided into 2 groups: those who receive alkylating agents (AK) and those who receive topoisomerase II inhibitors (TI). Patients with t-AML related to AK are characterized by a long interval between therapy and AML development and are associated with cytogenetic abnormalities involving chromosome 5 and 7. Patients with t-AML related to TI present with a shorter latency and are associated with karyotype aberrations involving chromosome 11 and 21 [1-5].
Overall, the prognosis of t-AML is worse than de novo AML, with a 5-year survival rate of less than 10% [6,7]. In contrast to de novo AML, in which various prognostic factors have been clearly defined [8,9], a comprehensive study focused on the identification of independent prognostic factors in t-AML has been lacking. Although several studies have reported that karyotype is an independent prognostic parameter in t-AML, these studies focused only on cytogenetic abnormalities and did not include molecular aberrations, cytotoxic therapy regimens, or hemograms as prognostic indicators [10-12]. Additionally, a recently published paper reviewed clinical and cytogenetic characteristics of 39 patients diagnosed with therapy-related myeloid neoplasms from a single center, but this study did not focus on t-AML nor the prognostic factors [13]. In this study, we performed a comprehensive evaluation to identify the independent prognostic factors in t-AML.
|
|
|
KEYWORD
|
|
|
Prognosis, Therapy, Related, AML
|
|
|
FullTexts / Linksout information
|
|
  
|
|
|
Listed journal information
|
|
  
|
|